EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 382 filers reported holding EXELIXIS INC in Q1 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,048,000 | +10.3% | 46,393 | -2.0% | 0.29% | 0.0% |
| Q4 2020 | $950,000 | -25.8% | 47,322 | -9.6% | 0.29% | -32.3% |
| Q3 2020 | $1,280,000 | +2.2% | 52,362 | -0.8% | 0.43% | -5.1% |
| Q2 2020 | $1,253,000 | +5.5% | 52,778 | -23.5% | 0.45% | -20.5% |
| Q1 2020 | $1,188,000 | -7.2% | 68,987 | -5.1% | 0.57% | +55.5% |
| Q4 2019 | $1,280,000 | -9.0% | 72,666 | -8.7% | 0.36% | -12.9% |
| Q3 2019 | $1,407,000 | -20.0% | 79,583 | -3.3% | 0.42% | -13.6% |
| Q2 2019 | $1,759,000 | -9.9% | 82,312 | +0.3% | 0.48% | -9.5% |
| Q1 2019 | $1,953,000 | +82.9% | 82,039 | +51.1% | 0.54% | +41.2% |
| Q4 2018 | $1,068,000 | -26.3% | 54,298 | -33.6% | 0.38% | -2.8% |
| Q3 2018 | $1,450,000 | +9.5% | 81,822 | +33.0% | 0.39% | +2.9% |
| Q2 2018 | $1,324,000 | -4.5% | 61,516 | -1.7% | 0.38% | -12.5% |
| Q1 2018 | $1,386,000 | -30.0% | 62,585 | -3.9% | 0.43% | -16.9% |
| Q4 2017 | $1,980,000 | – | 65,133 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 17,416,738 | $422,007,000 | 64.06% |
| Matrix Capital Management Company, LP | 15,117,460 | $366,296,000 | 11.71% |
| Rhenman & Partners Asset Management AB | 1,050,000 | $25,442,000 | 3.25% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 254,334 | $6,163,000 | 2.40% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 790,148 | $19,145,000 | 1.30% |
| Jupiter Investment Management Ltd | 4,182,760 | $101,348,000 | 1.06% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 50,818 | $1,231,000 | 0.70% |
| C M BIDWELL & ASSOCIATES LTD | 17,475 | $423,000 | 0.65% |
| QCM Cayman, Ltd. | 9,562 | $232,000 | 0.60% |
| Handelsinvest Investeringsforvaltning | 98,500 | $2,387,000 | 0.56% |